BERTHOLD, Frank, Marc HÖMBERG, Inna PROLESKOVSKAJA, Pavel MAZÁNEK, Margarita BELOGUROVA, Angela ERNST and Jaroslav ŠTĚRBA. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatric Hematology and Oncology. Philadelphia: Taylor & Francis, vol. 34, No 5, p. 308-319. ISSN 0888-0018. doi:10.1080/08880018.2017.1373314. 2017.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma
Authors BERTHOLD, Frank (276 Germany, guarantor), Marc HÖMBERG (276 Germany), Inna PROLESKOVSKAJA (112 Belarus), Pavel MAZÁNEK (203 Czech Republic, belonging to the institution), Margarita BELOGUROVA (643 Russian Federation), Angela ERNST (276 Germany) and Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution).
Edition Pediatric Hematology and Oncology, Philadelphia, Taylor & Francis, 2017, 0888-0018.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.154
RIV identification code RIV/00216224:14110/17:00102137
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1080/08880018.2017.1373314
UT WoS 000419983600006
Keywords in English Angiogenesis; dose-intense chemotherapy; immunomodulation; metronomic therapy; neuroblastoma
Tags EL OK, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 2/5/2019 13:10.
Abstract
The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experienced 1-3 recurrences and had 1-3 sites involved (osteomedullary, primary tumor, central nervous system, lymph nodes, liver, lungs) before the metronomic therapy started. Two patients in complete remission and three with active refractory disease following recurrence treatment were excluded from the outcome analysis. The curves for secondary event-free and overall survival demonstrated no significant differences.
PrintDisplayed: 29/3/2024 13:47